Abstract 1272P
Background
Non-small cell lung cancer (NSCLC) is a heterogeneous disease with various driver gene mutations. Currently, it remains unknown the differences in postoperative survival among patients with different genotypes. We previously constructed a clinical nomogram that effectively predicts postoperative survival in NSCLC patients (C-index 0.71), but whether integration of gene classification improves its efficacy remains unclear.
Methods
We collected data from patients representing six distinct driver genotypes at the First Affiliated Hospital of Guangzhou Medical University. Clinical characteristics and prognosis data were collected. We compared the overall survival, disease-free survival, and recurrence-free survival among different gene types. The previous prediction model was externally validated using the above data, and its predictive performance was assessed in populations with different genotypes. Furthermore, we constructed a novel survival prediction model by integrating gene subtyping and compared its predictive performance with that of the original model.
Results
1397 patients were enrolled in the analysis. Significant differences were observed in overall survival (P<0.05) and disease-free survival (P<0.05) and recurrence-free survival(P<0.05) among patients with different driver genotypes. The predictive model demonstrated good generalizability within our cohort (C-index: 0.71, 95% CI 0.68 to 0.74). However, the performance of the model varied across different genotypes. The clinical factor prediction model exhibited favorable applicability in patients with EGFR L858R mutation, EGFR 19 deletion mutation, and wild-type, but were not found in patients with rare EGFR mutations, RAS/BRAF mutations and fusion mutations. The new prediction model integrating genotypes slightly improves the performance of the previous clinical model (C-index: 0.74 vs 0.71).
Conclusions
Patients with different genotypes display diverse prognostic outcomes. The predictive model maintains practice predictive performance in certain driver gene subtypes. Furthermore, the integration of genotyping with clinical risk factors yields slight improvements in prediction performance.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1288P - Neoadjuvant therapy with anti-PD-1/PD-L1 plus platinum-base chemotherapy for resectable stage II-III non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials
Presenter: Maria Dacoregio
Session: Poster session 04
1289TiP - LANTERN study: A multi-omics digital human avatar for integrating precision medicine into clinical practice for lung cancer patients
Presenter: Emilio Bria
Session: Poster session 04
1294P - A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)
Presenter: Tetsuro Kondo
Session: Poster session 04
1296P - Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial
Presenter: Wei Guo
Session: Poster session 04
1297P - An open-label, prospective phase II study of tislelizumab in combination with chidamide as consolidation therapy in locally advanced, unresectable, stage III NSCLC
Presenter: Yi Hu
Session: Poster session 04
1298P - Chemotherapy with concurrent proton vs. photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and immune therapy
Presenter: Francesco Cortiula
Session: Poster session 04
1299P - The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study
Presenter: Lingjuan Chen
Session: Poster session 04
1300P - Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab
Presenter: Georg Evers
Session: Poster session 04